Trogarzo (ibalizumab-uiyk) is a prescription medication used in combination with other antiretroviral drugs in the treatment of human immunodeficiency virus (HIV) infection in adults who have multi-drug-resistant (MDR) HIV-1 and have tried and failed on other treatment options. Trogarzo is a monoclonal antibody that is administered intravenously every two weeks. Uses Trogarzo is used to treat HIV-1 infection in adults who have multi-drug resistant HIV-1 and have tried and failed on other antiretroviral drugs. It is used as part of a combination therapy approach with other antiretroviral drugs. Trogarzo, which is a monoclonal antibody, is unique in that it is the only HIV drug that targets the CD4 receptor on the surface of T-cells, which is the cell that HIV attacks, instead of targeting the virus itself. Dosage The recommended dose of Trogarzo is 2,000 mg administered intravenously over a period of one hour once every two weeks. Trogarzo should be administered by a healthcare provider in a healthcare setting. The dosage may be adjusted based on a patient's response to treatment. Demographic Trogarzo is indicated for use in adults with multi-drug-resistant HIV who have tried and failed on other antiretroviral drugs. Since MDR-HIV is a rare form of HIV, the demographic for Trogarzo treatment is limited to a niche population of HIV patients who have developed resistance to other drug therapies. Side Effects The most common side effects associated with Trogarzo treatment include diarrhea, dizziness, headache, nausea, rash, and vomiting. The incidence of these side effects is generally low. Serious side effects associated with Trogarzo treatment include allergic reactions, infections, and immune reconstitution inflammatory syndrome (IRIS). Patients should be monitored for signs of IRIS, which can occur when the immune system begins to rapidly recover after starting treatment. Interactions Trogarzo has no known drug interactions. However, it is always important to inform healthcare providers of all medications, including over-the-counter and herbal supplements, being taken. Generic Options Currently, there are no generic versions of Trogarzo available. In conclusion, Trogarzo is a prescription medication used to treat multi-drug-resistant HIV in adults who have failed on other treatment options. The recommended dosage is 2,000 mg administered intravenously every two weeks. Although the side effects associated with Trogarzo are generally low, serious side effects such as allergic reactions, infections, and IRIS can occur. Trogarzo has no known drug interactions and currently has no generic options available.